Vestal Point Capital’s Alto Neuroscience ANRO Stock Holding History

Vestal Point Capital’s Portfolio ANRO Stock Details ANRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$20.7M	Sell	785,000 -1,279,075	-62%	-$29.6M	0.48%	43
2026 Q1	$46.4M	Sell	2,064,075 -420,925	-17%	-$7.8M	1.3%	28
2025 Q4	$44.2M	Buy	2,485,000 +1,535,000	+162%	+$19.3M	1.5%	22
2025 Q3	$3.82M	Hold	950,000	–	–	0.17%	69
2025 Q2	$2.09M	Buy	950,000 +35,000	+4%	+$83.3K	0.11%	62
2025 Q1	$1.98M	Hold	915,000	–	–	0.14%	55
2024 Q4	$3.87M	Buy	915,000 +265,000	+41%	+$1.65M	0.23%	58
2024 Q3	$7.44M	Buy	650,000 +30,000	+5%	+$367K	0.56%	42
2024 Q2	$6.63M	Buy	620,000 +370,000	+148%	+$4.82M	0.49%	41
2024 Q1	$3.84M	Buy	+250,000	New	+$3.91M	0.32%	48

Other funds holding ANRO

AWG

Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SSC

Spruce Street Capital New York $510M AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Vestal Point Capital's ANRO Position: Q2 2026 in Review

Vestal Point Capital reduced its Alto Neuroscience (ANRO) stake by 62% in Q2 2026, selling an estimated $29.6M and leaving 785,000 shares worth $20.7M. The position accounts for 0.48% of the portfolio, ranked #43.

Vestal Point Capital first reported a position in ANRO in Q1 2024 and has held it in 10 quarters since. The position peaked at $46.4M in Q1 2026. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

Vestal Point Capital held 785,000 shares of Alto Neuroscience worth $20.7M as of Q2 2026.
Vestal Point Capital sold 1,279,075 Alto Neuroscience shares in Q2 2026, an estimated $29.6M.
Alto Neuroscience made up 0.48% of Vestal Point Capital's portfolio in Q2 2026, its #43 holding.
Vestal Point Capital first reported a position in Alto Neuroscience in Q1 2024 and has held it in 10 quarters since.
Vestal Point Capital's Alto Neuroscience position peaked at $46.4M in Q1 2026.
114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Vestal Point Capital's 13F filing for Q2 2026, filed 14 Aug 2026.